Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC

Cellular Immunology

Volumn 222, Issue 2, 2003, Pages 126-133

  Met, Özcan ^a   Buus, Søren ^a   Claesson, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cross presentation; Cytotoxic T lymphocyte; Dendritic cells; ELISPOT; Immunization; Interleukin 2; Ovalbumin

Indexed keywords

CD86 ANTIGEN; EPITOPE; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; OVALBUMIN[257-264]; PEPTIDE; PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; BONE MARROW; CELL ACTIVATION; CELL ASSAY; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG DESIGN; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE;

EID: 0037783968     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(03)00128-X     Document Type: Article

References (35)

1. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:2002;621-667.
2. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19:2001;47-64.
3. Yewdell J.W., Norbury C.C., Bennink J.R. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1999;1-77.
4. Jondal M., Schirmbeck R., Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity. 5:1996;295-302.
5. Mitchell D.A., Nair S.K., Gilboa E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur. J. Immunol. 28:1998;1923-1933.
6. Norbury C.C., Hewlett L.J., Prescott A.R., Shastri N., Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity. 3:1995;783-791.
7. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Thery C., Rescigno M., Saito T., Verbeek S., Bonnerot C., Ricciardi-Castagnoli P., Amigorena S. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:1999;371-380.
8. Larsson M., Fonteneau J.F., Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol. 22:2001;141-148.
9. Srivastava P.K., Menoret A., Basu S., Binder R.J., McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 8:1998;657-665.
10. Heath W.R., Carbone F.R. Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol. 1:2001;126-134.
11. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
12. Porgador A., Snyder D., Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:1996;2918-2926.
13. Paglia P., Chiodoni C., Rodolfo M., Colombo M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:1996;317-322.
14. Mayordomo J.I., Loftus D.J., Sakamoto H., De Cesare C.M., Appasamy P.M., Lotze M.T., Storkus W.J., Appella E., DeLeo A.B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines. J. Exp. Med. 183:1996;1357-1365.
15. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D. Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:1996;283-287.
16. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1999;1249-1255.
17. Schreurs M.W., Eggert A.A., de Boer A.J., Figdor C.G., Adema G.J. Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur. J. Immunol. 29:1999;2835-2841.
18. Kappler J.W., Skidmore B., White J., Marrack P. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med. 153:1981;1198-1214.
19. Grant E.P., Rock K.L. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J. Immunol. 148:1992;13-18.
20. Hugo P., Kappler J.W., Godfrey D.I., Marrack P.C. A cell line that can induce thymocyte positive selection. Nature. 360:1992;679-682.
21. Ardavin C., Martinez d.H., Martin P., Anjuere F., Arias C.F., Marin A.R., Ruiz S., Parrillas V., Hernandez H. Origin and differentiation of dendritic cells. Trends Immunol. 22:2001;691-700.
22. Labeur M.S., Roters B., Pers B., Mehling A., Luger T.A., Schwarz T., Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:1999;168-175.
23. Jung S., Unutmaz D., Wong P., Sano G., De los S.K., Sparwasser T., Wu S., Vuthoori S., Ko K., Zavala F., Pamer E.G., Littman D.R., Lang R.A. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 17:2002;211-220.
24. den Haan J.M., Lehar S.M., Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:2000;1685-1696.
25. Machy P., Serre K., Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 30:2000;848-857.
26. Norbury C.C., Chambers B.J., Prescott A.R., Ljunggren H.G., Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27:1997;280-288.
27. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature. 392:1998;86-89.
28. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:1999;362-368.
29. Kukutsch N.A., Rossner S., Austyn J.M., Schuler G., Lutz M.B. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J. Invest. Dermatol. 115:2000;449-453.
30. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
31. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den D.P., Brocker E.B., Steinman R.M., Enk A., Kampgen E., Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678.
32. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18:2000;245-273.
33. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:1994;163-175.
34. Rammensee H.G., Friede T., Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
35. Lauemoller S.L., Kesmir C., Corbet S.L., Fomsgaard A., Holm A., Claesson M.H., Brunak S., Buus S. Identifying cytotoxic T cell epitopes from genomic and proteomic information: the human MHC project. Rev. Immunogenet. 2:2000;477-491.